PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.10%
Revenue growth at 75-90% of AVGO's 7.50%. Bill Ackman would push for innovation or market expansion to catch up.
6.17%
Gross profit growth 1.25-1.5x AVGO's 4.49%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
15.50%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
15.25%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
14.66%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
16.67%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
16.92%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-1.40%
Share reduction while AVGO is at 2.71%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.52%
Reduced diluted shares while AVGO is at 1.06%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.30%
Dividend reduction while AVGO stands at 2.28%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
71.83%
Positive OCF growth while AVGO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
82.73%
Positive FCF growth while AVGO is negative. John Neff would see a strong competitive edge in net cash generation.
52.13%
10Y revenue/share CAGR under 50% of AVGO's 219.16%. Michael Burry would suspect a lasting competitive disadvantage.
6.46%
5Y revenue/share CAGR under 50% of AVGO's 184.50%. Michael Burry would suspect a significant competitive gap or product weakness.
12.10%
3Y revenue/share CAGR under 50% of AVGO's 164.70%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
48.23%
10Y OCF/share CAGR under 50% of AVGO's 696.78%. Michael Burry would worry about a persistent underperformance in cash creation.
24.14%
Below 50% of AVGO's 289.72%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
29.91%
3Y OCF/share CAGR under 50% of AVGO's 327.59%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
101.43%
Below 50% of AVGO's 340.48%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
7.87%
Below 50% of AVGO's 75.98%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
12.80%
Below 50% of AVGO's 53.03%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
33.75%
Equity/share CAGR of 33.75% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
16.21%
Below 50% of AVGO's 189.65%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-3.10%
Negative 3Y equity/share growth while AVGO is at 72.91%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
2216987.49%
Dividend/share CAGR of 2216987.49% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
182.59%
Dividend/share CAGR of 182.59% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
98.80%
3Y dividend/share CAGR at 50-75% of AVGO's 159.87%. Martin Whitman might see a weaker short-term approach to distributing cash.
3.28%
AR growth is negative/stable vs. AVGO's 6.73%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-6.05%
Inventory is declining while AVGO stands at 3.47%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-5.66%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-0.92%
We have a declining book value while AVGO shows 2.63%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-15.40%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-1.25%
Our R&D shrinks while AVGO invests at 9.96%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-7.66%
We cut SG&A while AVGO invests at 32.41%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.